Abstract Learning Objectives After completing this course, the reader will be able to:
Summarize the main characteristics and findings of randomized controlled trials evaluating …

Trastuzumab, a drug targeting human epidermal growth factor receptor 2, improves survival
rate in women with metastatic breast cancer. Symptomatic heart failure, a serious adverse …

Introduction Brain metastases (BM) occur in up to one third of patients with metastatic breast
cancer (MBC), whose incidences and prognoses by breast cancer subtypes in BM have not …

Anthracycline–trastuzumab-containing regimens demonstrate significant clinical activity in
human epidermal growth factor receptor 2 (HER2)-positive breast cancer; however, the …

For more than a decade the only therapies that were available for multiple sclerosis (MS)
were two immunomodulatory drugs—interferon beta and glatiramer acetate—and the …

The potential for cardiac toxicity in association with targeted biologic agents was first
observed with trastuzumab, a monoclonal antibody that targets the ErbB2/HER2 receptor. In …

Anthracyclines demonstrate significant disease activity in breast cancer and are a key
component of therapy in both early and advanced disease. It has been long recognized that …

Background: Trastuzumab has significantly improved the prognosis of breast cancer patients
overexpressing the human epidermal growth factor receptor 2 (HER2). This result has been …

Pharmacologic agents developed for cancer therapy have traditionally relied on a
therapeutic ratio of effects between tumors and normal tissue. Over the past decade, this …

Reactive oxygen species (ROS) are ubiquitous in the human body and play a pivotal role in
many chronic diseases, including cancer. The human body has developed a strong …